140 related articles for article (PubMed ID: 35960913)
1. Development and Validation of the PREMMplus Model for Multigene Hereditary Cancer Risk Assessment.
Yurgelun MB; Uno H; Furniss CS; Ukaegbu C; Horiguchi M; Yussuf A; LaDuca H; Chittenden A; Garber JE; Syngal S
J Clin Oncol; 2022 Dec; 40(35):4083-4094. PubMed ID: 35960913
[TBL] [Abstract][Full Text] [Related]
2. Pathogenic variants among females with breast cancer and a non-breast cancer reveal opportunities for cancer interception.
Bychkovsky BL; Lo MT; Yussuf A; Horton C; Hemyari P; LaDuca H; Garber JE; Scheib R; Rana HQ
Breast Cancer Res Treat; 2023 Jul; 200(1):63-72. PubMed ID: 36856935
[TBL] [Abstract][Full Text] [Related]
3. Utility of germline multi-gene panel testing in patients with endometrial cancer.
Karpel HC; Chern JY; Smith J M; Smith A J; Pothuri B
Gynecol Oncol; 2022 Jun; 165(3):546-551. PubMed ID: 35483985
[TBL] [Abstract][Full Text] [Related]
4. Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women.
Kurian AW; Hughes E; Handorf EA; Gutin A; Allen B; Hartman AR; Hall MJ
JCO Precis Oncol; 2017 Nov; 1():1-12. PubMed ID: 35172496
[TBL] [Abstract][Full Text] [Related]
5. New germline mutations in BRCA1, ATM, MUTYH, and RAD51D genes in Tuvans early-onset breast cancer patients.
Gervas P; Molokov A; Ivanova A; Panferova Y; Kiselev A; Chernyshova A; Pisareva L; Choynzonov E; Cherdyntseva N
Exp Oncol; 2021 Mar; 43(1):52-55. PubMed ID: 33785725
[TBL] [Abstract][Full Text] [Related]
6. Extended gene panel testing in lobular breast cancer.
van Veen EM; Evans DG; Harkness EF; Byers HJ; Ellingford JM; Woodward ER; Bowers NL; Wallace AJ; Howell SJ; Howell A; Lalloo F; Newman WG; Smith MJ
Fam Cancer; 2022 Apr; 21(2):129-136. PubMed ID: 33763779
[TBL] [Abstract][Full Text] [Related]
7. Investigating the prevalence of pathogenic variants in Saudi Arabian patients with familial cancer using a multigene next generation sequencing panel.
AlHarbi M; Mobark NA; AlJabarat WAR; ElBardis H; AlSolme E; Hamdan AB; AlFakeeh AH; AlMushawah F; AlHarthi F; AlSharm AA; Balbaid AAO; AlJohani N; Zhou AY; Robinson HA; Alqahtani SA; Abedalthagafi M
Oncotarget; 2023 Jun; 14():580-594. PubMed ID: 37306523
[TBL] [Abstract][Full Text] [Related]
8. Racial and ethnic variation in multigene panel testing in a cohort of BRCA1/2-negative individuals who had genetic testing in a large urban comprehensive cancer center.
Tatineni S; Tarockoff M; Abdallah N; Purrington KS; Assad H; Reagle R; Petrucelli N; Simon MS
Cancer Med; 2022 Mar; 11(6):1465-1473. PubMed ID: 35040284
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer.
Pearlman R; Frankel WL; Swanson B; Zhao W; Yilmaz A; Miller K; Bacher J; Bigley C; Nelsen L; Goodfellow PJ; Goldberg RM; Paskett E; Shields PG; Freudenheim JL; Stanich PP; Lattimer I; Arnold M; Liyanarachchi S; Kalady M; Heald B; Greenwood C; Paquette I; Prues M; Draper DJ; Lindeman C; Kuebler JP; Reynolds K; Brell JM; Shaper AA; Mahesh S; Buie N; Weeman K; Shine K; Haut M; Edwards J; Bastola S; Wickham K; Khanduja KS; Zacks R; Pritchard CC; Shirts BH; Jacobson A; Allen B; de la Chapelle A; Hampel H;
JAMA Oncol; 2017 Apr; 3(4):464-471. PubMed ID: 27978560
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
[TBL] [Abstract][Full Text] [Related]
11. [The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition].
Moretta J; Berthet P; Bonadona V; Caron O; Cohen-Haguenauer O; Colas C; Corsini C; Cusin V; De Pauw A; Delnatte C; Dussart S; Jamain C; Longy M; Luporsi E; Maugard C; Nguyen TD; Pujol P; Vaur D; Andrieu N; Lasset C; Noguès C;
Bull Cancer; 2018 Oct; 105(10):907-917. PubMed ID: 30268633
[TBL] [Abstract][Full Text] [Related]
12. Multigene Panel Testing Yields High Rates of Clinically Actionable Variants Among Patients With Colorectal Cancer.
Coughlin SE; Heald B; Clark DF; Nielsen SM; Hatchell KE; Esplin ED; Katona BW
JCO Precis Oncol; 2022 Nov; 6():e2200517. PubMed ID: 36370464
[TBL] [Abstract][Full Text] [Related]
13. High frequency of pathogenic non-founder germline mutations in
Maksimenko J; Irmejs A; Trofimovičs G; Bērziņa D; Skuja E; Purkalne G; Miklaševičs E; Gardovskis J
Hered Cancer Clin Pract; 2018; 16():12. PubMed ID: 29928469
[TBL] [Abstract][Full Text] [Related]
14. Splicing profile by capture RNA-seq identifies pathogenic germline variants in tumor suppressor genes.
Landrith T; Li B; Cass AA; Conner BR; LaDuca H; McKenna DB; Maxwell KN; Domchek S; Morman NA; Heinlen C; Wham D; Koptiuch C; Vagher J; Rivera R; Bunnell A; Patel G; Geurts JL; Depas MM; Gaonkar S; Pirzadeh-Miller S; Krukenberg R; Seidel M; Pilarski R; Farmer M; Pyrtel K; Milliron K; Lee J; Hoodfar E; Nathan D; Ganzak AC; Wu S; Vuong H; Xu D; Arulmoli A; Parra M; Hoang L; Molparia B; Fennessy M; Fox S; Charpentier S; Burdette J; Pesaran T; Profato J; Smith B; Haynes G; Dalton E; Crandall JR; Baxter R; Lu HM; Tippin-Davis B; Elliott A; Chao E; Karam R
NPJ Precis Oncol; 2020; 4():4. PubMed ID: 32133419
[TBL] [Abstract][Full Text] [Related]
15. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
[TBL] [Abstract][Full Text] [Related]
16. [Retrospective NGS Study in High-risk Hereditary Cancer Patients at Masaryk Memorial Cancer Institute].
Macháčková E; Hazova J; Sťahlová Hrabincová E; Vašíčková P; Navrátilová M; Svoboda M; Foretová L
Klin Onkol; 2016; 29 Suppl 1():S35-45. PubMed ID: 26691941
[TBL] [Abstract][Full Text] [Related]
17. New germline BRCA2 gene variant in the Tuvinian Mongol breast cancer patients.
Gervas P; Klyuch B; Denisov E; Kiselev A; Molokov A; Pisareva L; Malinovskaya E; Choynzonov E; Cherdyntseva N
Mol Biol Rep; 2019 Oct; 46(5):5537-5541. PubMed ID: 31273614
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and spectrum of pathogenic variants among patients with multiple primary cancers evaluated by clinical characteristics.
Bychkovsky BL; Lo MT; Yussuf A; Horton C; Richardson M; LaDuca H; Garber JE; Rana HQ
Cancer; 2022 Mar; 128(6):1275-1283. PubMed ID: 34875721
[TBL] [Abstract][Full Text] [Related]
19. Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: analysis of a 21 gene panel in the Brazilian population.
da Costa E Silva Carvalho S; Cury NM; Brotto DB; de Araujo LF; Rosa RCA; Texeira LA; Plaça JR; Marques AA; Peronni KC; Ruy PC; Molfetta GA; Moriguti JC; Carraro DM; Palmero EI; Ashton-Prolla P; de Faria Ferraz VE; Silva WA
BMC Med Genomics; 2020 Feb; 13(1):21. PubMed ID: 32039725
[TBL] [Abstract][Full Text] [Related]
20. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]